Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions

Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft

“…Induction of GvL is associated with induction of GvHD after DLI. [12][13][14] Patients developing acute GvHD (aGvHD) after DLI seem to have a better outcome than patients without GvHD. 13 Most centers use the number of CD3 þ cells  10 6 /kg recipient body weight to define T-cell doses.…”

“…[12][13][14] Patients developing acute GvHD (aGvHD) after DLI seem to have a better outcome than patients without GvHD. 13 Most centers use the number of CD3 þ cells  10 6 /kg recipient body weight to define T-cell doses. A total cell dose of 10  10 6 CD3 þ cells/kg for related donors seems to be safe and effective, 13,14 but no consensus on the optimal dosage of DLI has yet been reached.…”

“…13 Most centers use the number of CD3 þ cells  10 6 /kg recipient body weight to define T-cell doses. A total cell dose of 10  10 6 CD3 þ cells/kg for related donors seems to be safe and effective, 13,14 but no consensus on the optimal dosage of DLI has yet been reached. 11,15 G-CSF is routinely used to mobilize CD34-positive hematopoietic stem cells from healthy volunteer donors before leukapheresis.…”

Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation

“…6 A number of factors were shown to be related with improved survival after DLI: long interval between SCT and relapse, chronic CML phase at relapse, molecular or cytogenetic grade of relapse, low initial DLI cell dose and escalated-dose DLI regimen. 6,7,[10][11][12][13][14][15] However, the majority of analyses regarding DLI in CML have been performed based on data of patients transplanted more than a decade ago, when most patients received a BM graft. Thus the results of treatment might have changed in the context of alloPBSCT in CML.…”

Clofarabine as a potential stimulant of alloreactivity

“…Several factors, such as histocompatibility or sex mismatch between donor and recipient, as well as the CD3 þ T-cell dose infused, are classical determinants of alloreactivity. 7,8 In clinical practice, some patients even exposed to these factors appear resistant to alloreactivity, as they never display any sign of GVHD after HSCT and DLI. In these cases, the adjunction of a supplementary T-cell stimulation by chemotherapyinduced lymphopenia might improve the efficacy of DLI.…”